• 11 hours Saudis Eye Billions As Stocks Get Emerging Market Boost
  • 14 hours Airbnb In Acquisition Mode Ahead Of IPO
  • 17 hours Gold Hangs At $1,300 Ahead Of Fed Meeting
  • 19 hours Champagne Sales Slow As European Economic Worries Grow Louder
  • 1 day Putin Signs “Digital Iron Curtain” Into Law
  • 2 days Russian Metals Magnate Sues U.S. Over Sanctions
  • 2 days Tesla Looks To Jump Into Indian Market
  • 2 days Global Banks Lay Groundwork To Re-Inflate Asset Prices
  • 2 days Homeowners Experiment With Risky New Investment Trend
  • 3 days U.S. Tech Stocks Look Increasingly Vulnerable
  • 3 days De Beers To Expand World’s Most Profitable Diamond Mine
  • 3 days Ford CEO Gets Raise After Massive Layoff Round
  • 3 days Germany’s Flirtation With Recession Could Cripple The Global Economy
  • 4 days Where To Look As Gold Miners Inch Higher
  • 4 days Google Faces Billions In Fines From European Regulators
  • 5 days The Energy Industry Has A Millennial Problem
  • 5 days Russian Banks Scramble For Sanction Loopholes
  • 6 days Gold ETFs Take A Hit After Four-Month Run
  • 6 days European Union Takes Aim At Ten New Tax Havens
  • 7 days Goldman Defends Trillion-Dollar Corporate Buyback Spree
Tesla Looks To Jump Into Indian Market

Tesla Looks To Jump Into Indian Market

Elon Musk is not giving…

The Energy Industry Has A Millennial Problem

The Energy Industry Has A Millennial Problem

Talented millennials with science and…

Michael Kern

Michael Kern

Safehaven

Michael Kern is a newswriter and editor at Safehaven.com, Oilprice.com, and a writer at Crypto Insider. Michael has several years of experience covering cryptocurrencies, and…

Contact Author

  1. Home
  2. News
  3. Breaking News

FDA Turns Its Back On “The Fountain Of Youth”

Blood

Legend is that Keith Richards of Rolling Stones went regularly to Swiss medical clinics to get his blood replaced in a bid to beat his lifestyle. It was just a legend, and never proven. But fast forward a couple of decades and we have Baby Boomers looking in greater numbers for that “fountain of youth”.

They think they found it, but the Federal Drug Administration (FDA) says “no”.

What the FDA is saying “no” to is this: An increasing number of companies offering injections of blood from younger people to combat the signs of aging. Last week, the FDA issued a statement expressing concern that “some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies.”

“Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them, and are potentially harmful,” the FDA said.

The agency also said that some companies are selling plasma transfusions as supposed "treatments" for conditions like normal aging, memory loss, dementia, Parkinson’s disease, multiple sclerosis…

Even though the statement didn't call out any companies by name, it was clearly targeting the best-known among these—California-based Ambrosia Medical, which since 2017, Ambrosia ‘anti-aging” treatment for $8,000 for one liter of blood and $12,000 for two Related: Is Bitcoin Heading For A Bull Run?

Following the FDA’s warning, Ambrosia’s on Tuesday changed its website to state that it had “ceased patient treatments”.  

While the company says that most participants “see improvements” from the one-time infusion of a two-liter bagful of plasma, scientists and clinicians call it a scam.

But an opportunity is knocking hard on this vampire quest—and some won’t be able to resist.

Even the big dogs are toying with the idea. Google’s parent company, Alphabet, has invested heavily in its secretive anti-aging spinout, called Calico.

Celularity, a biotech giant Celgene spinoff, raised $250 million last year to try to use postpartum placentas to delay the aging process.

And then there is a company called Elysium Health, which has talked Nobel Prize winners into selling a $50-per-month supplement aimed at promoting longevity.

Related: Major Investment Banks Turn Bullish On Copper

Last year, one Florida-based former mortician and doctor announced the launch of a clinical trial giving participants blood infusions from young donors for $285,000 “enrollment” fee.

A couple of years ago, some U.S. citizens were reportedly hospitalized after traveling to Germany as “medical tourists” for a controversial treatment involving injections with sheep cells. They allegedly visited Germany twice a year for this type of treatment—involving fetal cells from sheep-which is not permitted in the U.S. The treatment is said to be used for everything from impotence to migraines, as well as anti-aging.

But from the FDA’s perspective, this is the 21st Centuries snake oil—and none of it has been proven.

By Michael Kern for Safehaven.com

More Top Reads From Safehaven.com:

Back to homepage

Leave a comment
  • Panskeptic on February 28 2019 said:
    You are flat-out wrong to lump Elysium Basis in with the other treatments. MIT is a respected scientific institution, and somehow I don't see a bunch of Nobel Prize-winners as gullible innocents.

    Go back and do some more research. This was just plain sloppy reporting.

Leave a comment